white → orange1 → green2
5-MeO-DiPT
5-Methoxy-N,N-diisopropyltryptamine
Foxy, Foxy Methoxy
5-MeO-DiPT is a synthetic psychedelic of the tryptamine class1 first described by Alexander Shulgin in 19802. It is considered an atypical psychedelic, characterized by prominent stimulating and mildly entactogenic effects rather than typical visual distortions. The compound is particularly noted for producing strong tactile and sexual enhancement alongside auditory distortions similar to those of the related compound DiPT. Higher doses are frequently reported to produce an unpleasant body load.
Dosage & Duration
Dosage
Threshold~3 mg
Light3-10 mg
Moderate10-15 mg
Strong15-20 mg
Heavy20+ mg
Duration
Onset20-40 minutes
Come Up10-50 minutes
Peak2-5 hours
Offset3-5 hours
After Effects2-3 hours
Total4-8 hours
Subjective Effects
5-MeO-DiPT occupies an unusual position among the tryptamines, producing a primarily body-centered experience with stimulant- and entactogen-like qualities rather than a classically visionary psychedelic state. The experience is dominated by a strong bodily energy or buzzing sensation, pronounced tactile and sexual enhancement, and only light perceptual alterations, with full effects arriving within roughly the first hour of onset. Effects are sometimes described as wave-like, ebbing and flowing in intensity, and reports of deeply engrossing visions or hallucinations are notably absent even at strong doses.
Physical
The body load is prominent and polarizing: a buzzing muscular energy accompanied by stimulation, sweating, muscle tension, and jaw clenching. Gastrointestinal effects are characteristic, including stomach discomfort, gas, markedly increased peristalsis, and diarrhea, and many users find it difficult to sleep for 4-12 hours after the peak.
Stimulation
The substance is distinctly stimulating in both body and mind, producing a buzzing muscular energy that some users enjoy and others find aversive; restlessness is common.
Uncomfortable
Gastrointestinal disturbance is a well-known signature of the substance, though it does not affect all users.
Cognitive
The headspace tends toward euphoria, emotional openness, and an outgoing, socially oriented mental activation rather than deep introspection or intuitive insight. Time frequently feels slowed, particularly during the come-up, and some users experience confusion, ego softening, or an anxious edge to the stimulation.
Disruptive
Emotional
The emotional tone is generally positive and opening, though the stimulation can carry an anxious or unnerving edge, especially when the body load becomes uncomfortable.
Visual
Visual effects are light relative to most psychedelic tryptamines, consisting mainly of subtle enhancements and distortions; closed-eye imagery appears mainly at higher doses, and fully formed hallucinations are not reported.
Distortions
Auditory
Auditory effects lean toward distortion rather than enhancement; music can sound strange, fake, or shifted in a manner reminiscent of DiPT, and many users find music less engaging than usual.
Tactile
Tactile enhancement is a defining feature of the substance, with the entire body feeling alive and alert; touch takes on a strongly sensual or erotic quality for many users.
Olfactory
Gustatory
Pharmacology
Pharmacodynamics
5-MeO-DiPT acts as a non-selective serotonin receptor agonist with activity at the 5-HT1A, 5-HT1B, 5-HT1D, 5-HT2A, 5-HT2B, and 5-HT2C receptors.3 Binding affinity is strongest at the 5-HT1A receptor, reported as 2-fold to 161-fold greater than at 5-HT2A across studies. In functional assays, however, activation potency is similar at 5-HT1A and 5-HT2A, with several-fold lower potency at 5-HT2C. The psychedelic effects are thought to result primarily from 5-HT2A receptor agonism.34 5-MeO-DiPT also acts as a serotonin reuptake inhibitor with variable reported potency, while showing no significant dopamine or norepinephrine reuptake inhibition and no monoamine releasing activity.5 In rodent models, the compound elevates brain serotonin levels (presumably via serotonin reuptake inhibition) and may also increase dopamine levels through an unknown mechanism, though findings on the latter are mixed.36
Pharmacokinetics
Human urine analyses identify three principal pathways: O-demethylation to 5-OH-DiPT, hydroxylation at the 6-position to 6-OH-5-MeO-DiPT, and N-deisopropylation to 5-MeO-NIPT. The two hydroxylated metabolites are excreted in part as sulfate and glucuronide conjugates and were more abundant than 5-MeO-NIPT in the examined specimens.7 In pooled human liver microsomes and recombinant-enzyme experiments, CYP2D6 was the major enzyme for O-demethylation to 5-OH-DiPT. CYP1A2, CYP2C8, and CYP3A4 were the major enzymes assigned to N-deisopropylation. These are in-vitro enzyme findings and do not quantify the effect of CYP genotype or inhibitors in living people.8 Parent 5-MeO-DiPT remained detectable in urine up to 35 hours after dosing in the specimens examined, but this is a urinary detection observation, not an elimination half-life. Controlled human values for bioavailability, Cmax, Tmax, clearance, volume of distribution, and terminal half-life have not been established by these studies.78
Dangerous
Highest riskThese combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.
Unsafe
AvoidThere is considerable risk of physical harm when taking these combinations, they should be avoided where possible.
Caution
Use cautionThese combinations are not usually physically harmful, but may produce undesirable effects, such as physical discomfort or overstimulation. Extreme use may cause physical health issues. Synergistic effects may be unpredictable. Care should be taken when choosing to use this combination.
Harm Potential
Addiction & Dependence
Psychological
Extremely LowLike other serotonergic psychedelics, 5-MeO-DiPT is not habit-forming.10 Evidence remains limited, but related tryptamines are not typically described as addictive or prone to compulsive use.
Toxicity
Central Nervous System
Serotonergic neurotoxicity has been demonstrated in rodent models, with cognitive deficits in spatial navigation, cognitive flexibility, and attention observed following adolescent exposure; effects are described as less severe than those of MDMA, and human relevance remains unclear.11
Renal
Rhabdomyolysis and acute renal failure have been reported in the context of overdose; this appears to be an acute toxicity concern rather than a chronic use issue.13
Psychosis Risk
One report describes a prolonged delusional state associated with 5-MeO-DiPT.14 Those whose family history includes schizophrenia or early-onset mental illness should be cautious, because psychedelics may trigger latent psychological or mental problems.
History & Culture
5-MeO-DiPT was first synthesized and tested by American chemist Alexander Shulgin2, who conducted the initial human trials of the compound in 1975. Shulgin subsequently co-authored a paper with M. F. Carter detailing the synthesis and human psychopharmacology of both 5-MeO-DiPT…
Legality
International
5-MeO-DiPT does not appear in the official schedules to the 1961 Single Convention, the 1971 Convention on Psychotropic Substances, or the Tables of the 1988 Convention. International scheduling of other tryptamines does not itself schedule 5-MeO-DiPT.
By Country
United StatesIllegalSchedule I
21 CFR § 1308.11(d)48
Emergency scheduled by the DEA on April 4, 200349, then formally placed into Schedule I of the Controlled Substances Act on September 29, 2004.5051 Manufacturing, possession, buying, selling, and distribution require a DEA license.52
By state
Across the 50 states, D.C., and the permanent territories, most jurisdictions treat 5-MeO-DiPT consistently with federal control; listed entries record independently verified differences in state classification or coverage.
MassachusettsNot scheduledNot listed in Massachusetts classes
BrazilIllegalLista F2
Listed on Portaria SVS/MS nº 344. Possession, production, and sale are prohibited under national health surveillance regulations.
ChinaIllegalCategory I
Notice on adjusting the Catalogue of Narcotic Drugs and Psychotropic Substances23
Controlled substance as of October 2015. Sale, purchase, import, export, and manufacture are prohibited under SFDA regulations.
FinlandRestrictedLiite
5-MeO-DiPT is listed in the appendix to Government Decree 1130/2014 as a psychoactive substance prohibited from the consumer market. The decree classifies the listed substances under Finland's consumer-market restriction rather than, by itself, as narcotics.
GermanyIllegalAnlage I
Betäubungsmittelgesetz, Anlage I28
Listed in Schedule I of the Betäubungsmittelgesetz (Narcotics Act)28 since October 10, 2000. Manufacturing, possession, import, export, purchase, sale, and dispensing without license are prohibited.
ItalyIllegalTabella I
Decreto del Ministero della Salute 13 febbraio 202329
Italy includes 5-MeO-DiPT in Table I of its controlled-substances tables. Table I covers substances with high abuse potential that are not used therapeutically.
LatviaIllegalList I
Cabinet Regulation No. 847, Regulations regarding Narcotic Substances, Psychotropic Substances and Precursors to be Controlled in Latvia32
Classified as a controlled substance under Latvian national drug legislation.
NorwayIllegalNarkotika
Forskrift om narkotika (narkotikaforskriften), narkotikalisten34
Norway’s narcotics list names 5-MeO-DiPT as 5-metoksy-N,N-diisopropyltryptamin. The listing makes it a narcotic drug under the Norwegian narcotics-control regime.
RussiaIllegalсписок I
Government Resolution of the Russian Federation No. 681 of 30 June 1998, ‘On approval of the list of narcotic drugs, psychotropic substances and their precursors subject to control in the Russian Federation,’ as amended by Government Resolution No. 822 of 6 October 201136
5-MeO-DiPT is prohibited in Russia as a derivative of dimethyltryptamine (DMT) under List I of Government Resolution No. 681. List I covers narcotic drugs, psychotropic substances, and precursors whose circulation in the Russian Federation is prohibited under Russian law and Russia’s international treaties.
SpainNot scheduledNot listed
5-MeO-DiPT is not named in any list of Annex 1 to Real Decreto 2829/1977, Spain’s current consolidated psychotropic-substances schedules. The decree subjects the substances in Lists I–IV to its controls, while its later amendments add newly controlled psychoactive substances to those lists by name. 5-MeO-DiPT is therefore not controlled under those named national psychotropic schedules.
SwitzerlandControlled (Verzeichnis E)Citation needed
Specifically named as a controlled substance under Verzeichnis E of Swiss narcotics regulations.
AustriaRestrictedNPS group
Austria’s NPS legislation controls defined chemical substance groups rather than relying only on individual names. The tryptamine group in the implementing regulation encompasses 5-MeO-DiPT, and the NPSG prohibits placing covered substances on the market.
CanadaIllegalSchedule III
Controlled Drugs and Substances Act, Schedule III22
Not listed in Canada's schedules of controlled substances under the Controlled Drugs and Substances Act (CDSA) as of available documentation.
DenmarkIllegalBilag 1
Bekendtgørelse om euforiserende stoffer, bilag 124
Controlled since February 20, 2004. Possession outside of licensed research and medical contexts is prohibited.
FranceIllegalStupéfiant
Arrêté du 22 février 1990 fixant la liste des substances classées comme stupéfiants27
France classifies 5-MeO-DiPT as a narcotic substance in the national narcotics schedule. The listing applies the controls attached to substances classified as stupéfiants.
GreeceControlled substance
Designated a controlled substance on February 18, 2003 under national drug control legislation.
JapanIllegalNarcotic
Prohibited since April 17, 2005 under Japanese drug control laws.
New ZealandIllegal (analog/blanket ban)Class C analogue
Misuse of Drugs Act 1975, section 233
May be treated as a Class C controlled drug under analogue provisions due to structural similarity to DMT.
PolandIllegalNew psychoactive substance
Regulation of the Minister of Health on lists of psychotropic substances, narcotic drugs and new psychoactive substances35
Poland lists 5-MeO-DiPT in its register of new psychoactive substances. The national register brings the substance within Poland’s statutory controls for new psychoactive substances.
SingaporeIllegalClass A
Misuse of Drugs Act, First Schedule37
Controlled as a Class A substance since early 2006. Trafficking penalties include imprisonment ranging from 5 to 20 years and caning.
SwedenRestrictedHälsofarlig vara
Förordning (1999:58) om förbud mot vissa hälsofarliga varor; Lag (1999:42) om förbud mot vissa hälsofarliga varor414243
5-MeO-DiPT is listed as a hälsofarlig vara (health-hazardous good) in the annex to Sweden’s Förordning (1999:58) om förbud mot vissa hälsofarliga varor. Under Lag (1999:42), handling the listed substance without a permit is prohibited, including importation, transfer, manufacture, acquisition, offering for sale, and possession. It is not listed in the current Förteckning I narcotics schedule published by Läkemedelsverket.
UkraineIllegalList I
Ukraine lists 5-MeO-DIPT among especially dangerous psychotropic substances in List I. The listing places the substance under the strict national controls applicable to List I psychotropic substances.
References
Source Pages
Citations
- Drug Enforcement Administration, Diversion Control Division. (October 2025). 5-METHOXY-N,N-DIISOPROPYLTRYPTAMINE (Street Names: Foxy, or Foxy methoxy). U.S. Drug Enforcement Administration. https://www.deadiversion.usdoj.gov/drug_chem_info/5meodipt.pdf12
- A. T. Shulgin, & M. F. Carter. (1980). N, N-Diisopropyltryptamine (DIPT) and 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT). Two orally active tryptamine analogs with CNS activity. Commun Psychopharmacol, 4(5), 363–369. https://bitnest.netfirms.com/external/Commun.Psychopharmacol/4.5.363123
- Karolina Noworyta-Sokołowska, Katarzyna Kamińska, Grzegorz Kreiner, Zofia Rogóż, & Krystyna Gołembiowska. (November 2016). Neurotoxic Effects of 5-MeO-DIPT: A Psychoactive Tryptamine Derivative in Rats. Neurotox Res, 30(4), 606–619. https://doi.org/10.1007/s12640-016-9654-012345678910
- Kaixi Li, Nan Li, Yuanyuan Chen, Xiangyu Li, Yanling Qiao, Dan Wang, Bin Di, & Peng Xu. (September 2025). Effects of three tryptamines: alpha-methyltryptamine, 5-methoxy-alpha-methyltryptamine, and 5-methoxy- N , N -diisopropyltryptamine on acute toxicity, locomotor activity, and hallucinogenic behavior in mice. Behav Pharmacol, 36(6), 429–437. https://doi.org/10.1097/fbp.00000000000008411
- Bruce E. Blough, Antonio Landavazo, Ann M. Decker, John S. Partilla, Michael H. Baumann, & Richard B. Rothman. (October 2014). Interaction of psychoactive tryptamines with biogenic amine transporters and serotonin receptor subtypes. Psychopharmacology (Berl), 231(21), 4135–4144. https://doi.org/10.1007/s00213-014-3557-7123
- Yoko Hagino, Frank Scott Hall, George R. Uhl, Ichiro Sora, & Kazutaka Ikeda. (March 2021). Dual actions of 5-MeO-DIPT at the serotonin transporter and serotonin 5-HT1A receptor in the mouse striatum and prefrontal cortex. Neuropsychopharmacol Rep, 41(1), 91–101. https://doi.org/10.1002/npr2.121611
- Metabolism of the psychotomimetic tryptamine derivative 5-methoxy-N,N-diisopropyltryptamine in humans: identification and quantification of its urinary metabolites. pubmed.ncbi.nlm.nih.gov (n.d.). https://doi.org/10.1124/dmd.105.005835123
- Shizuo Narimatsu, Rei Yonemoto, Keita Saito, Kazuo Takaya, Takuya Kumamoto, Tsutomu Ishikawa, Masato Asanuma, Masahiko Funada, Kimio Kiryu, Shinsaku Naito, Yuzo Yoshida, Shigeo Yamamoto, & Nobumitsu Hanioka. (April 2006). Oxidative metabolism of 5-methoxy-N,N-diisopropyltryptamine (Foxy) by human liver microsomes and recombinant cytochrome P450 enzymes. Biochem Pharmacol, 71(9), 1377–1385. https://doi.org/10.1016/j.bcp.2006.01.015123
- 5-MeO-DiPT Basics. Erowid (2015-02-10). https://erowid.org/chemicals/5meo_dipt/5meo_dipt_basics.shtml123
- David E. Nichols. (April 2016). Psychedelics. Pharmacol Rev, 68(2), 264–355. https://doi.org/10.1124/pr.115.01147812
- David M. Compton, Kerri L. Dietrich, Melissa C. Selinger, & Erin K. Testa. (May 2011). 5-methoxy-N,N-di(iso)propyltryptamine hydrochloride (Foxy)-induced cognitive deficits in rat after exposure in adolescence. Physiol Behav, 103(2), 203–209. https://doi.org/10.1016/j.physbeh.2011.01.0211
- Karolina Noworyta-Sokołowska, Katarzyna Kamińska, Joanna Rzemieniec, Agnieszka Wnuk, Jakub Wojcieszak, Anna Maria Górska, Grzegorz Kreiner, Małgorzata Kajta, & Krystyna Gołembiowska. (2019). Effects of exposure to 5-MeO-DIPT during adolescence on brain neurotransmission and neurotoxicity in adult rats. Forensic Toxicol, 37(1), 45–58. https://doi.org/10.1007/s11419-018-0433-x1
- Gheath Alatrash, Navneet S. Majhail, & James C. Pile. (April 2006). Rhabdomyolysis after ingestion of "foxy," a hallucinogenic tryptamine derivative. Mayo Clin Proc, 81(4), 550–551. https://doi.org/10.4065/81.4.5501
- Yasuko Fuse-Nagase, & Toru Nishikawa. (April 2013). Prolonged delusional state triggered by repeated ingestion of aromatic liquid in a past 5-methoxy-N, N-diisopropyltryptamine abuser. Addict Sci Clin Pract, 8(1). https://doi.org/10.1186/1940-0640-8-91
- Alexander Shulgin, & Ann Shulgin. (1997). TiHKAL: The Continuation. Transform Press. https://www.erowid.org/library/books_online/tihkal/tihkal37.shtml12
- Susan C. Smolinske, Rahul Rastogi, & Stephen Schenkel. (December 2005). Foxy methoxy: a new drug of abuse. J Med Toxicol, 1(1), 22–25. https://doi.org/10.1007/bf0316090112
- Duo Shan, Mao-He Yu, Jie Yang, Ming-Hua Zhuang, Zhen Ning, Hui Liu, Lu Liu, Meng-Jie Han, & Da-Peng Zhang. (December 2018). Correlates of HIV infection among transgender women in two Chinese cities. Infect Dis Poverty, 7(1). https://doi.org/10.1186/s40249-018-0508-21
- Neue-Psychoaktive-Substanzen-Gesetz (NPSG) and Neue-Psychoaktive-Substanzen-Verordnung. ris.bka.gv.at (n.d.). https://ris.bka.gv.at/GeltendeFassung.wxe?Abfrage=Bundesnormen&Gesetzesnummer=200076051
- Neue-Psychoaktive-Substanzen-Gesetz (NPSG) and Neue-Psychoaktive-Substanzen-Verordnung. ris.bka.gv.at (n.d.). https://ris.bka.gv.at/GeltendeFassung.wxe?Abfrage=Bundesnormen&Gesetzesnummer=200076061
- Portaria SVS/MS nº 344/1998, Lista F2 (as amended by RDC nº 49/2015). gov.br (n.d.). https://www.gov.br/anvisa/pt-br/assuntos/medicamentos/controlados/lista/arquivos-controlados/6560json-file-1/%40%40download/file/6560json-file-1.pdf1
- Portaria SVS/MS nº 344/1998, Lista F2 (as amended by RDC nº 49/2015). bvsms.saude.gov.br (n.d.). https://bvsms.saude.gov.br/bvs/saudelegis/anvisa/2015/rdc0049_11_11_2015.pdf1
- Controlled Drugs and Substances Act, Schedule III. laws-lois.justice.gc.ca (n.d.). https://laws-lois.justice.gc.ca/eng/acts/C-38.8/page-15.html#h-956021
- Notice on adjusting the Catalogue of Narcotic Drugs and Psychotropic Substances. nmpa.gov.cn (n.d.). https://www.nmpa.gov.cn/xxgk/ggtg/qtggtg/20150929000001664.html1
- Bekendtgørelse om euforiserende stoffer, bilag 1. retsinformation.dk (n.d.). https://www.retsinformation.dk/eli/lta/2022/2441
- Valtioneuvoston asetus kuluttajamarkkinoilta kielletyistä psykoaktiivisista aineista 1130/2014. finlex.fi (n.d.). https://finlex.fi/fi/lainsaadanto/saadoskokoelma/2014/11301
- Valtioneuvoston asetus kuluttajamarkkinoilta kielletyistä psykoaktiivisista aineista 1130/2014. finlex.fi (n.d.). https://www.finlex.fi/fi/laki/ajantasa/2014/201411301
- Arrêté du 22 février 1990 fixant la liste des substances classées comme stupéfiants. legifrance.gouv.fr (n.d.). https://www.legifrance.gouv.fr/loda/id/JORFTEXT000000533085/1
- Gesetz über den Verkehr mit Betäubungsmitteln: Anlage I. (2019). https://www.gesetze-im-internet.de/btmg_1981/anlage_i.html12
- Decreto del Ministero della Salute 13 febbraio 2023. gazzettaufficiale.it (n.d.). https://www.gazzettaufficiale.it/eli/id/2023/02/23/23A01113/sg1
- Narcotics and Psychotropics Control Act designation order. mhlw.go.jp (n.d.). https://www.mhlw.go.jp/houdou/2004/12/h1202-2.html1
- Narcotics and Psychotropics Control Act designation order. mhlw.go.jp (n.d.). https://www.mhlw.go.jp/houdou/2005/08/h0802-3.html1
- Cabinet Regulation No. 847, Regulations regarding Narcotic Substances, Psychotropic Substances and Precursors to be Controlled in Latvia. likumi.lv (n.d.). https://likumi.lv/ta/en/en/id/121086-regulations-regarding-narcotic-substances-psychotropic-substances-and-precursors-to-be-controlled-in-latvia1
- Misuse of Drugs Act 1975, section 2. legislation.govt.nz (n.d.). https://www.legislation.govt.nz/act/public/1975/0116/latest/DLM436190.html1
- Forskrift om narkotika (narkotikaforskriften), narkotikalisten. lovdata.no (n.d.). https://lovdata.no/dokument/LTI/forskrift/2024-02-29-3571
- Regulation of the Minister of Health on lists of psychotropic substances, narcotic drugs and new psychoactive substances. eli.gov.pl (n.d.). https://eli.gov.pl/api/acts/DU/2024/1139/text.html1
- Government Resolution of the Russian Federation No. 681 of 30 June 1998, ‘On approval of the list of narcotic drugs, psychotropic substances and their precursors subject to control in the Russian Federation,’ as amended by Government Resolution No. 822 of 6 October 2011. pravo.gov.ru (n.d.). http://pravo.gov.ru/proxy/ips/?docbody=&nd=1020539281
- Misuse of Drugs Act, First Schedule. sso.agc.gov.sg (n.d.). https://sso.agc.gov.sg/Act/MDA1973?ProvIds=Sc1-1
- Real Decreto 2829/1977, de 6 de octubre. boe.es (n.d.). https://www.boe.es/buscar/act.php?id=BOE-A-1977-271601
- Real Decreto 2829/1977, de 6 de octubre. boe.es (n.d.). https://www.boe.es/eli/es/o/2026/04/13/snd3621
- Real Decreto 2829/1977, de 6 de octubre. aemps.gob.es (n.d.). https://www.aemps.gob.es/medicamentos-de-uso-humano/estupefacientes-y-psicotropos/1
- Sveriges riksdag. (n.d.). Förordning (1999:58) om förbud mot vissa hälsofarliga varor. Sveriges riksdag. https://www.riksdagen.se/sv/dokument-och-lagar/dokument/svensk-forfattningssamling/forordning-199958-om-forbud-mot-vissa_sfs-1999-58/1
- Förordning (1999:58) om förbud mot vissa hälsofarliga varor; Lag (1999:42) om förbud mot vissa hälsofarliga varor. riksdagen.se (n.d.). https://www.riksdagen.se/sv/dokument-och-lagar/dokument/svensk-forfattningssamling/lag-199942-om-forbud-mot-vissa-halsofarliga_sfs-1999-42/1
- Förordning (1999:58) om förbud mot vissa hälsofarliga varor; Lag (1999:42) om förbud mot vissa hälsofarliga varor. lakemedelsverket.se (n.d.). https://www.lakemedelsverket.se/sv/lagar-och-regler/foreskrifter/2011-10-konsoliderad1
- Cabinet of Ministers Resolution No. 770, as amended by Resolution No. 796 of 27 July 2011. zakon.rada.gov.ua (n.d.). https://zakon.rada.gov.ua/laws/show/796-2011-%D0%BF#Text1
- Cabinet of Ministers Resolution No. 770, as amended by Resolution No. 796 of 27 July 2011. zakon.rada.gov.ua (n.d.). https://zakon.rada.gov.ua/laws/show/770-2000-%D0%BF#Text1
- Misuse of Drugs Act 1971, Schedule 2, Part I. legislation.gov.uk (n.d.). https://www.legislation.gov.uk/ukpga/1971/38/schedule/21
- UK Legislation. (n.d.). Misuse of Drugs Act 1971, Schedule 2, Part I. legislation.gov.uk. https://www.legislation.gov.uk/ukpga/1971/38/schedule/2/part/I1
- 21 CFR § 1308.11(d). ecfr.gov (n.d.). https://www.ecfr.gov/current/title-21/chapter-II/part-1308/section-1308.111
- Department of Justice Drug Enforcement Administration (Dea). (April 2003). Schedules of controlled substances: temporary placement of alpha-methyltryptamine and 5-methoxy-N,N-diisopropyltryptamine into Schedule I. Final rule. Fed Regist, 68(65), 16427–16430. https://pubmed.ncbi.nlm.nih.gov/12678045/1
- Department of Justice Drug Enforcement Administration (Dea). (September 2004). Schedules of controlled substances: placement of alpha-methyltryptamine and 5-methoxy-N,N-diisopropyltryptamine into schedule I of the Controlled Substances Act. Final rule. Fed Regist, 69(188), 58950–58953. https://pubmed.ncbi.nlm.nih.gov/15455477/1
- US Government Publishing Office. (2023). 21 CFR 1308.11 -- Schedule I. Code of Federal Regulations, Title 21, Volume 9. https://www.govinfo.gov/content/pkg/CFR-2023-title21-vol9/xml/CFR-2023-title21-vol9-sec1308-11.xml1
- US Government Publishing Office. (2023). 21 CFR 1301.11 -- Persons required to register. Code of Federal Regulations, Title 21, Volume 9. https://www.govinfo.gov/content/pkg/CFR-2023-title21-vol9/xml/CFR-2023-title21-vol9-sec1301-11.xml1
- Mass. Gen. Laws ch. 94C, § 31. malegislature.gov (n.d.). https://malegislature.gov/Laws/GeneralLaws/PartI/TitleXV/Chapter94C/Section311
Further Reading
- Noworyta-Sokolowska et al. (2016). Neurotoxicity Research
Ray, T. S. (2010). Psychedelics and the Human Receptorome- Shulgin, A. T.; Carter, M. F. (1980). Communications in Psychopharmacology
- Reviewed & approved
Reviewed, edited, and approved by subject-matter expert Lyrea.
Automated synthesisInformation aggregated and synthesized using an autonomous workflow built by Josie Kins.
Suggest an edit
Spotted a mistake, an outdated claim, or something missing from the 5-MeO-DiPT article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.
Wish to give generalised feedback? You can do so here.